

A randomised, double-blind, placebo-controlled trial of Vitamin D supplementation in the management of symptomatic knee osteoarthritis (the VIDEO study)

Submission date 05/04/2005	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered
		<input type="checkbox"/> Protocol
Registration date 03/05/2005	Overall study status Completed	<input type="checkbox"/> Statistical analysis plan
		<input checked="" type="checkbox"/> Results
Last Edited 20/03/2017	Condition category Musculoskeletal Diseases	<input type="checkbox"/> Individual participant data

Plain English summary of protocol

http://www.ctu.mrc.ac.uk/research_areas/study_details.aspx?s=43

Contact information

Type(s)

Scientific

Contact name

Dr Richard Keen

Contact details

Metabolic Unit
Royal National Orthopaedic Hospital Stanmore
Brockley Hill
Stanmore
United Kingdom
HA7 4LP

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers

Study information

Scientific Title

A randomised, double-blind, placebo-controlled trial of Vitamin D supplementation in the management of symptomatic knee osteoarthritis (the VIDEO study)

Acronym

VIDEO (Vitamin D Evaluation in Osteoarthritis)

Study objectives

Vitamin D supplementation may reduce the rate of disease progression and improve symptoms in participants with knee osteoarthritis.

On 29/03/2011 the anticipated end date was changed from 31/01/2009 to 31/08/2011.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Not provided at time of registration

Study design

Randomised double-blind placebo-controlled trial

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Study setting(s)

Hospital

Study type(s)

Treatment

Participant information sheet

Not available in web format, please use the contact details below to request a patient information sheet

Health condition(s) or problem(s) studied

Knee osteoarthritis

Interventions

Participants will be randomised to receive oral vitamin D (as cholecalciferol) 800 IU/day (20 µg /day) or matching placebo tablets.

Intervention Type

Supplement

Phase

Not Applicable

Drug/device/biological/vaccine name(s)

Vitamin D

Primary outcome measure

Radiological progression of knee OA in medial joint compartment at 36 months

Secondary outcome measures

1. Radiological progression of knee OA in other joint compartments
2. Reduction in pain and functional disability
3. Improvement in quality of life

Overall study start date

01/02/2004

Completion date

31/08/2011

Eligibility

Key inclusion criteria

1. Participants aged over 50
2. Male or female
3. Ambulatory (not wheelchair bound)
4. Able and willing to attend or comply with treatment and follow-up
5. Radiological evidence of early disease at medial tibio-femoral knee compartment (modified Kellgren & Lawrence [k&l] score 2/3, joint space width [JSW] >1 mm)
6. Pain in knee for most days of previous month
7. Written informed consent

Participant type(s)

Patient

Age group

Adult

Sex

Both

Target number of participants

800 (478 achieved as of 08/08)

Key exclusion criteria

1. Secondary osteoarthritis (OA), septic arthritis, gout, Wilson's disease, Paget's disease, pseudo gout
2. History of inflammatory arthritis

3. Knee stiffness >30 minutes duration
4. Current user of cod liver oil or vitamin D supplementation
5. Current use of glucosamine or chondroitin for less than 3 months
6. History of hyperparathyroidism or osteomalacia
7. Current use of anti-epileptic medication
8. Current use of bisphosphonates or use within 2 years
9. History of hypercalcaemia or hypercalciuria
10. History of hyperthyroidism, sarcoidosis
11. History of renal stones
12. Previous intra-articular injection: steroid within 3 months, hyalgan within 6 months
13. Previous knee surgery or arthroscopy within 6 months
14. History of osteoporotic fracture
15. History of cancer within last 5 years, excluding skin cancer
16. Serious psychiatric disorders including dementia
17. Inability to understand the procedures
18. Inability to attend or comply with treatment or follow-up scheduling
19. Pregnancy

Date of first enrolment

01/02/2004

Date of final enrolment

31/08/2011

Locations

Countries of recruitment

England

United Kingdom

Study participating centre

Metabolic Unit

Stanmore

United Kingdom

HA7 4LP

Sponsor information

Organisation

Royal National Orthopaedic Hospital (UK)

Sponsor details

RNOH Stanmore

Brockley Hill

Stanmore

United Kingdom
HA7 4LP

Sponsor type
Not defined

ROR
<https://ror.org/043j9bc42>

Funder(s)

Funder type
Charity

Funder Name
Arthritis Research Campaign 15622

Results and Publications

Publication and dissemination plan
Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

IPD sharing plan summary
Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	01/11/2016		Yes	No
Results article	sub study results	01/09/2017		Yes	No